BRAF and thyroid nodule: Molecular markers, such as the BRAF V600E mutation or the TERT mutation, have been well studied in large cohorts, and the management of thyroid nodules harboring these mutations has also been recommended in the American and the European Thyroid Association Guidelines [18,19].